ASH 2016 | First results from Bgb-3111 in CLL and Waldenström’s macroglobulinemia
Constantine Tam, MD from the Peter MacCallum Cancer Centre, Melbourne, Australia gives an overview of the Phase I trial of BTK inhibitor Bgb-3111 in chronic lymphocytic leukemia (CLL) and Waldenström’s macroglobulinemia. Bgb-3111 is similar to ibrutinib as it binds the same active sites irreversibly. It is, however, more specific and selective for BTK. In the CLL patients, the drug is well-tolerated and they demonstrated complete tissue inhibition of BTK. The response rate is 96% with no complete remissions (CR) to date. In Waldenström’s macroglobulinemia, deep BTK inhibition was achieved with a response rate of 94% and very good partial response rate (VGPR) of 34%. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
